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AbstrACt
background Individuals on renal replacement therapy 
(RRT) have increased fracture risk, but risk in less 
advanced chronic kidney disease (CKD) is unclear.
Objective To investigate CKD associations with hip 
fracture incidence and mortality.
Design Record linkage cohort study Grampian Laboratory 
Outcomes Mortality and Morbidity Study II.
setting Single health region in Scotland.
Participants All individuals (≥15 years) with sustained 
CKD stages 3–5 and those on RRT, and a 20% random 
sample of those with normal renal function, in the resident 
population in 2003.
Outcome measures Outcomes were (1) incident hip 
fracture measured with (A) admissions or (B) deaths, 
with at least 5.5 years follow-up and (2) post-hip fracture 
mortality. Unadjusted and adjusted, incident rate ratios 
(IRRs) and mortality rate ratios were calculated using 
Poisson regression.
results Of 39 630 individuals identified in 2003 (41% 
males, mean age 63.3 years), 19 537 had CKD stages 
3–5, 345 were on RRT and 19 748 had normal estimated 
glomerular filtration rate (eGFR). Hip fracture incidence, 
measured by admissions, was increased in CKD stages 
3–5 (compared with normal eGFR), both overall (adjusted 
IRR 1.49 (95% CI 1.24 to 1.79)) and for individual CKD 
stages 3a, 3b and 4. Hip fracture incidence, measured 
using deaths, was increased in those with CKD stages 3b 
and 4. Post-hip fracture mortality was only increased in 
CKD stage 4. There was only a small number of individuals 
and events for CKD stage 5, resulting in insufficient 
statistical power.
Conclusion Hip fracture incidence was higher in CKD 
stages 3–5 compared with normal eGFR. Post-hip fracture 
mortality was only increased in CKD stage 4. Reducing hip 
fracture incidence in CKD through regular fall and fracture 
risk review should reduce overall deaths after hip fracture 
in the population.
IntrODuCtIOn 
Hip fractures are a major public health 
issue recognised in national clinical guide-
lines, and more common in women and the 
elderly.1 2 In the UK, there is an estimated 
70 000–90 000 hip fractures annually.1 Hip 
fracture is associated with high mortality; 
up to one-third of people die within a year.3 
The associated morbidity and economic cost 
is large, with the annual cost of hip fractures 
estimated at ~£2 billion for the UK.1 
Chronic kidney disease (CKD) is also a 
major and growing healthcare challenge, 
with an estimated global prevalence of 
11%–13%, again higher in the elderly and 
women.4 People with CKD are at increased 
risk of morbidity, mortality and progressive 
kidney function decline, leading to renal 
replacement therapy (RRT).5–7 A well-rec-
ognised complication of RRT is renal bone 
disease. The association between RRT and 
risk of hip fracture is well established, with a 
high incidence of hip fractures.8 Mortality at 
1-year post-hip fracture is 55%–64% for dial-
ysis patients,8 9 a 2.7-fold increase compared 
with the non-fractured dialysis population.8 9
Although changes in bone metabolism are 
seen in patients with CKD long before the 
initiation of RRT,10 the evidence of hip frac-
ture risk in CKD is uncertain, particularly at 
less advanced stages. Some studies report on 
renal function measured after hip fracture 
strengths and limitations of this study
 ► A large, population-based cohort using valid meth-
ods for assessing comorbidity and identifying indi-
viduals with chronic kidney disease (CKD).
 ► Reporting hip fracture incidence using both admis-
sion and death records, allowing direct comparison 
with studies that have used either of these meth-
ods and highlighting the importance of methods of 
measurement.
 ► Using at least two serum creatinine measurements 
to identify CKD, thus reducing the risk of identifying 
episodes of acute kidney injury as CKD.
 ► Use of hospital episode data to ascertain hip frac-
ture, acknowledging that a small number of hip frac-
tures may not lead to hospital admission.
 ► We only considered hip fractures acknowledging 
that CKD may be associated with other fracture 
sites; however, hip fractures would have more com-
plete admission data.
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has occurred,11 12 others restrict to those at high risk of 
fracture.13 Recent studies reporting hip fracture inci-
dence in those with prior documented CKD have been 
conflicting, some showing an association14–16 and others 
not.17 In addition, an increased risk of hip fracture-re-
lated deaths has been reported only among those with 
more advanced CKD.18 Mortality post-hip fracture is high 
regardless of renal function,3 although CKD has been 
linked to higher post-hip fracture mortality in hospital19 
and at 1 year20 compared with those with normal renal 
function. Overall, however, many previous studies 
reporting the effect of CKD on the incidence of hip frac-
ture or mortality post-hip fracture are limited by: older 
populations15 16 18 20; CKD based on only one measure-
ment of renal function15 17 18 20 or reliance on administra-
tive coding for identification of CKD.16 19
With an increasing and ageing population, both the 
prevalence of CKD and hip fracture incidence will rise, 
together with associated health and social care costs. As 
a result of uncertainty about the association between 
CKD and hip fracture, current guidelines on fracture 
risk management may be poorly targeted. Therefore, the 
study aim was to clarify the association of CKD with hip 
fracture incidence and mortality.
MethODs
Population
The Grampian Laboratory Outcomes Mortality and 
Morbidity Study II (GLOMMS-II) cohort consists of resi-
dents (≥15 years) in a single health region in the North-
east of Scotland (population ~0.5 million) in 2003. All 
with at least one abnormal measure of kidney function 
(estimated glomerular filtration rate (eGFR) <60 mL/
min/1.73 m2); a 20% random sample with normal kidney 
function; a 20% random sample with no measurement of 
kidney function and all on maintenance RRT (dialysis and 
transplants) were included, as described previously.21–23 
A single biochemistry service processes all blood samples 
(inpatient, outpatient and community) for the region. 
For this study, individuals with sustained CKD stages 3–5 
(not dialysis or transplant), on maintenance RRT (dialysis 
and transplants), and those with normal kidney function 
are reported only.
The study protocol was reviewed by Information Services 
Division Privacy Advisory Committee, NHS Grampian 
Caldicott Guardian, North of Scotland Research Ethics 
Service and University of Aberdeen College Ethics Review 
Board (CERB). The study was carried out in accordance 
with the principles of the Declaration of Helsinki.
exposure
Renal status was assessed at entry to study. CKD was defined 
and staged according to Kidney Disease: Improving Global 
Outcomes (KDIGO).24 25 The index value and date were 
defined as the first abnormal kidney function measure, 
(eGFR <60 mL/min/1.73 m2), calculated from a creat-
inine measured between 1 January and 31 December 
2003 (see footnote in table 1).26 To fulfil the criteria of 
CKD, the next eGFR at least 3 months after index (or 
if there were no samples after 3 months postindex, the 
eGFR prior to 3 months before the index) also had to 
be <60 mL/min/1.73 m2. In those with normal kidney 
function throughout 2003 (eGFR ≥60 mL/min/1.73 m2), 
the last value and date were taken as the index.
Covariates
Other covariates included age, sex, proteinuria, comor-
bidity, rurality and deprivation. Proteinuria was assessed 
using the last urinary albumin to creatinine or protein to 
creatinine ratio measured prior to index, and categorised 
as not measured, normoalbuminuric, microalbuminuric 
or macroalbuminuric (see footnote in table 1). Comor-
bidities were identified from hospital episode records for 
the 5 years prior to 2003 (International Classification of 
Diseases, 10th Revision (ICD-10) coding). A modified 
Charlson Comorbidity Index score was calculated27 28 (see 
footnote in online supplementary table 1). Postal code-
based rurality29 and deprivation30 categories were also 
obtained (see table 1 and footnote in online supplemen-
tary table 1).
Follow-up
From index date in 2003, follow-up was available to 30 
June 2009, giving an observation period of at least 5.5 
years.
Outcomes
The primary outcome was hip fracture incidence, 
measured using (1) hip fracture admission (from hospital 
admissions data, where hip fracture was recorded as the 
main or additional diagnosis (ICD-10 code S72)) and (2) 
hip fracture-related death (from national death records, 
where hip fracture was recorded as a main or other cause 
of death). The secondary outcome was post-hip fracture 
mortality in individuals who had a hip fracture admission, 
both (1) all-cause mortality (ACM) and (2) specifically 
hip fracture-related mortality (HFM) where hip fracture 
was recorded as main or other cause of death.
exclusions
Those who had a hip fracture or died on index date, and 
non-residents of Grampian were excluded.
Data linkage
The Community Health Index number, a unique patient 
identifier used throughout the Scottish healthcare system, 
was used to link GLOMMS-II with hospital episode and 
death registry data using deterministic matching. The 
deidentified dataset was hosted by Grampian Data Safe 
Haven, allowing secure controlled access for researchers 
while ensuring data security.31
statistical analyses
Hip fracture incidence rates were calculated using both 
(1) hip fracture admissions and (2) hip fracture deaths, 
as ‘markers’ for hip fracture occurrence. Follow-up time 
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for hip fracture admissions (figure 1i(A)) was calcu-
lated from index date (study entry) to the date of the 
first hospital admission for hip fracture, censoring at 
death or end of follow-up. Follow-up time for hip frac-
ture deaths (figure 1i(B)) was calculated from index date 
to date of hip fracture-related death, censoring at end 
of follow-up or date of death from other causes. Unad-
justed and adjusted incident rate ratios (IRRs) for the 
effect of CKD on hip fracture incidence were calculated 
using Poisson regression with an offset of person-years of 
exposure. Models for hip fracture admission incidence 
were developed using forward selection of variables, both 
using variables with significant effect on univariate anal-
ysis and specifically for available risk factors for fractures 
(see footnote  in table 2) identified from national guide-
lines.32 Variables were included if they improved model 
performance (likelihood ratio test). The final model for 
hip fracture death incidence was adjusted for age and sex 
only.
Post-hip fracture mortality follow-up time was calcu-
lated from the date of a hip fracture-related hospital 
admission to date of death, censoring at end of follow-up 
Table 1 Characteristics of individuals with and without a 
hip fracture admission
Characteristic
Hip fracture, 
n (%)
No hip fracture, 
n (%) 
Total no of patients: 39 630 1084 (2.7) 38 546 (97.3) 
Renal status*
  RRT 8 (0.7) 337 (0.9) 
  CKD stages 3–5 915 (84.4) 18 622 (48.3) 
  CKD stage 5 2 (0.2) 180 (0.5) 
  CKD stage 4 77 (7.1) 1321 (3.4) 
  CKD stage 3b 320 (29.5) 4941 (12.8) 
  CKD stage 3a 516 (47.6) 12 180 (31.6) 
  Normal eGFR 161 (14.9) 19 587 (50.8) 
Sex
  Males 231 (21.3) 16 137 (41.9)
  Females 853 (78.7) 22 409 (58.1)
  Age, mean (95% CI), 
years
80.3 
(79.7 to 80.8)
62.8 
(62.6 to 63.0)
  15–44 10 (0.9) 7278 (18.9)
  45–54 13 (1.2) 4533 (11.8)
  55–64 42 (3.9) 6203 (16.1)
  65–74 172 (15.9) 8805 (22.8)
  75–84 516 (47.6) 8583 (22.3)
  ≥85 331 (30.5) 3144 (8.2)
Creatinine, median (IQR), 
µmol/L
99.5 
(85.5–121.1)
88.7 
(73.6–109.2)
eGFR (MDRD), mean (95% 
CI), mL/min/1.73 m2† 
50.6 
(49.5 to 51.7)
66.5 
(66.3 to 66.8)
Proteinuria‡
  Normal 79 (7.3) 2888 (7.5)
  Microalbuminuric 47 (4.3) 957 (2.5)
  Macroalbuminuric 13 (1.2) 683 (1.8)
  Not measured 945 (87.2) 34 018 (88.3)
  ACR, median (IQR), mg/
mmol 1.0 (0.9–5.0) 1.0 (0.9–3.0)
  PCR, median (IQR), mg/
mmol
21.5 
(10.0–49.0)
25.0 
(10.0–79.0)
Charlson Comorbidity Index score
  0 699 (64.5) 29 547 (76.7)
  1–2 297 (27.4) 7156 (18.6)
  3–4 69 (6.4) 1301 (3.4)
  ≥5 19 (1.8) 542 (1.4)
Urban rural classification§
  Large urban 448 (41.3) 13 512 (35.1)
  Other urban 155 (14.3) 5536 (14.4)
  Accessible small towns 99 (9.1) 3096 (8.0)
  Remote small towns 112 (10.3) 3146 (8.2)
  Accessible rural 159 (14.7) 6851 (17.8)
  Remote rural 106 (9.8) 3664 (9.5)
Continued
Characteristic
Hip fracture, 
n (%)
No hip fracture, 
n (%) 
SIMD (quintile)§
  1 (most deprived) 87 (8.0) 2414 (6.3)
  2 182 (16.8) 5794 (15.0)
  3 286 (26.4) 8994 (23.3)
  4 260 (24.0) 9377 (24.3)
  5 (least deprived) 264 (24.4) 9226 (23.9)
*Renal status based on KDIGO CKD stages: overall CKD 
stages 3–5, index eGFR <60 mL/min/1.73 m2; individual 
stages 3a, 3b, 4 and 5 CKD, index eGFR 59–45, 44–30, 
29–15 and <15 mL/min/1.73 m2. CKD stage 5 does not 
include dialysis or transplants.
†eGFR was calculated using the four-variable isotope 
dilution mass spectrometry aligned MDRD formula as is 
used clinically in the region.
‡Proteinuria status defined as: not measured: 
no test prior to index date; normoalbuminuric: 
measured, not microalbuminuric /macroalbuminuric; 
microalbuminuric: ≥2.5 mg/mmol ACR for men, ≥3.5 mg/
mmol ACR for women or PCR ≥15 for both; 
macroalbuminuric: ≥30 mg/mmol ACR for both men and 
women or ≥50 mg/mmol PCR.
§SIMD quintile and urban rural classification were unknown 
for 2746 individuals because of missing postal codes. 
Where relevant, missing data were included in the analysis 
as a separate category.
ACR, albumin to creatinine ratio; CKD, chronic kidney 
disease; eGFR, estimated glomerular filtration rate; 
MDRD, Modification of Diet in Renal Disease; RRT, renal 
replacement therapy (dialysis and transplants); SIMD, 
Scottish Index of Multiple Deprivation; KDIGO, Kidney 
Disease: Improving Global Outcomes.
Table 1 Continued 
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for ACM (figure 1ii(A)), and for HFM, date of death from 
other causes also (figure 1ii(B)). Mortality rates were 
calculated. Unadjusted and adjusted mortality rate ratios 
(MRRs) were calculated using Poisson regression. The 
final adjusted model for each outcome (ACM and HFM) 
was developed as above. Assumptions were checked 
including proportionality over time. As there was a low 
number of individuals and events in the RRT group, this 
group was reported in the descriptive statistics only, but 
not included in the hip fracture or mortality post-hip frac-
ture risk analyses. Where measures of effect were calcu-
lated, 95% CIs were reported. Analyses were performed 
using StataV.13.0.
results
baseline characteristics
The flow diagram for generating GLOMMS-II and identi-
fying individuals for this study is shown in figure 2. There 
were 19 537 individuals with CKD stages 3–5, 345 on RRT 
and 19 748 with normal eGFR (20% random sample). 
Those with CKD were older (mean age 74.8 (95% CI 74.6 
to 74.9) years), and more likely to be female (64.9%) 
than those with normal eGFR (52.1 (95% CI 51.8 to 52.3) 
years, 52.8%) or on RRT (54.4 (95% CI 52.7 to 56.2) 
years, 44.9%) respectively. Individuals with CKD had 
more comorbidity than those with normal eGFR (33.3% 
vs 13.8% with Charlson Comorbidity Index score ≥1) 
(online supplementary table 1).
hip fracture incidence (primary outcome)
Hip fracture incidence was assessed using both (1) hip 
fracture admissions and (2) hip fracture-related deaths as 
measures of occurrence.
There were 915 hip fracture admissions for individuals 
with CKD stages 3–5, 8 among those on RRT and 161 for 
those with normal eGFR. Compared with those with no 
hip fracture admission, individuals with a hip fracture 
were more likely to be female, older, have more comor-
bidity and have CKD stages 3–5 (table 1). As there were 
few fracture admissions among individuals on RRT, these 
individuals’ results are not reported further.
CKD stages 3–5 overall was associated with an increased 
incidence of hip fracture admission compared with 
Figure 1 Entry to the study, follow-up time and censoring for (i) hip fracture incidence and (ii) post-hip fracture mortality. The 
index date was defined as the first abnormal eGFR (<60 mL/min/1.73 m2) from a creatinine measured between 1 January and 
31 December 2003. Where all eGFR values in 2003 were normal, the last value and date were taken as the index. Primary 
outcome, hip fracture incidence measured using (A) hip fracture admission (from hospital admissions data, where hip fracture 
was recorded as the main or additional diagnosis (ICD-10 code S72)) and (B) hip fracture-related  death (from national death 
records, where hip fracture was recorded as a main or other cause of death). Secondary outcome, post-hip fracture mortality 
in individuals who had a hip fracture admission, both (A) all-cause mortality (ACM) and (B) specifically hip fracture-related 
mortality (HFM) where hip fracture was recorded as main or other cause of death. eGFR, estimated glomerular filtration rate; 
ICD-10, International Classification of Diseases, 10th Revision. 
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those with normal eGFR, rates of 10.0 (95% CI 9.4 to 
10.7) and 1.5 (95% CI 1.2 to 1.7) per 1000 patient-years 
(PY), respectively. The unadjusted hip fracture admis-
sion IRR for CKD stages 3–5 overall compared with 
normal eGFR was 6.90 (95% CI 5.83 to 8.15) (table 2a). 
This was increased in both men and women, unadjusted 
IRR 5.28 (95% CI 3.89 to 7.16) and 6.85 (95% CI 5.59 
to 8.38), respectively (online supplementary table 2). 
The increased risk was present for every age group, but 
more marked in younger age groups, the unadjusted 
IRR (CKD stages 3–5 vs normal eGFR) was 7.63 (95% 
CI 1.54 to 37.82) and 1.48 (95% CI 1.14 to 1.91) for 
those aged 15–44 and 75–84 years, respectively (online 
supplementary table 2). After adjusting for age, sex, 
comorbidity, deprivation, proteinuria and rurality (final 
model), hip fracture risk remained increased for CKD 
stages 3–5 overall (IRR 1.49 (95% CI 1.24 to 1.79)) and 
for CKD stages 3a, 3b and 4 individually. There were, 
however, only small numbers of individuals and events 
for CKD stage 5. The model adjusting for available frac-
ture risk factors identified from national guidelines32 
showed similar results (table 2a).
Hip fracture incidence was also assessed with hip 
fracture-related deaths as a measure of occurrence. 
Few individuals died with a hip fracture-related death; 
1.0% of those with CKD stages 3–5 and 0.2% of those 
with normal eGFR. This equates to 2.1 (1.9–2.5) versus 
0.3 (0.2–0.4) per 1000 PY respectively; an eightfold 
difference. After adjusting for age and sex (table 2b), 
the overall IRR for CKD stages 3–5 effect was 1.27 
(0.85–1.88). However, individual CKD stages 3b and 4 
were still associated with hip fracture incidence when 
Figure 2 Flow diagram of study population from GLOMMS-II. CKD, chronic kidney disease; eGFR, estimated  glomerular   
filtration rate; GLOMMS-II, Grampian Laboratory Outcomes Morbidity and Mortality Study II; RRT, renal replacement therapy 
(dialysis and transplants).
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measured with death. Fifteen individuals had no hip 
fracture admission recorded, but had a hip fracture-re-
lated death.
Post-hip fracture mortality (secondary outcome)
Among the 915 individuals with CKD stages 3–5 and 161 
with normal eGFR who had a hip fracture admission, 
there were subsequently 666 and 83 all-cause; and 183 
and 26 hip fracture-related deaths, respectively. Four 
patients died on hip fracture admission date and there-
fore excluded from further analysis. Compared with 
those alive at the end of follow-up, individuals who died 
were older (mean age 82.6 (82.1–83.2)) vs 74.7 (73.6–
75.8) years), had more comorbidity (Charlson Comor-
bidity Index score ≥1, 42.0% vs 21.4%) and more had 
CKD stages 3–5 (89.0% vs 75.9%).
Post-hip fracture ACM rates for those who had a hip 
fracture admission were 488.0 (452.4–526.6) and 308.9 
(249.1–383.0) per 1000 PY for those with CKD stages 3–5 
and normal eGFR, respectively (table 3a). CKD stages 
3–5 overall were initially associated with ACM. However, 
after adjusting for age, sex, comorbidity, deprivation, 
proteinuria and rurality (final model), only the post-hip 
fracture ACM MRR for CKD stage 4 was increased (2.04 
(1.44–2.89)).
Post-hip fracture HFM rates for individuals who had 
a hip fracture admission were 134.1 (95% CI 116.0 to 
155.0) and 96.8 (95% CI 65.9 to 142.1) per 1000 PY for 
those with CKD stages 3–5 overall and normal eGFR, 
respectively (table 3b). The unadjusted HFM MRR for 
CKD stages 3–5 overall was 1.39 (95% CI 0.92 to 2.09). 
After adjusting for age, sex, comorbidity, deprivation, 
proteinuria and rurality (final model), CKD stages 3–5 
overall remained not associated with post-hip fracture 
HFM (MRR 0.79 (95% CI 0.51 to 1.22)), however, CKD 
stage 4 remained associated (adjusted MRR 1.88 (95% 
CI 1.02 to 3.47)).
Discussion
The incidence of hip fracture measured by admissions 
was increased in those with CKD stages 3–5 overall, 
and for individual CKD stages 3a, 3b and 4 compared 
with those with normal eGFR, particularly in younger 
age groups. The incidence of hip fracture measured by 
deaths was also increased in those with CKD stages 3b 
and 4. Post-hip fracture mortality, however, whether ACM 
or HFM, was not increased in CKD stages 3–5 overall, 
although it was for CKD stage 4. There were, however, 
only small numbers of individuals and events for CKD 
stage 5.
The mechanisms underlying the association between 
CKD and fractures are likely to be at the metabolic level, 
due to abnormalities in the parathyroid–calcium– phos-
phate axis as a result of reduced kidney function.33 In 
Table 3 Post-hip fracture admission mortality in CKD, both (a) all-cause mortality and (b) hip fracture-related mortality
Renal status
Total 
with hip 
fracture
Events, 
n
PY 
follow-
up (1000)
Rate per 1000 PY
(95% CI)
Unadjusted
MRR (95% CI)
Adjusted*
MRR (95% CI)
final model
(a) All-cause mortality post-hip fracture
  CKD stages 3–5† 915 666 1.4 488.0 (452.4 to 526.6) 1.58 (1.26 to 1.99) 1.09 (0.85 to 1.39)
  CKD stage 5b† 2 2 0.0 764.1 (191.1 to 3055.3) 2.47 (0.61 to 10.06) 1.04 (0.24 to 4.51)
  CKD stage 4 77 71 0.1 885.3 (701.6 to 1117.1) 2.87 (2.09 to 3.93) 2.04 (1.44 to 2.89)
  CKD stage 3b 320 240 0.4 542.2 (477.7 to 615.3) 1.76 (1.37 to 2.25) 1.11 (0.85 to 1.45)
  CKD stage 3a 516 353 0.8 420.7 (379.0 to 466.9) 1.36 (1.07 to 1.73) 1.02 (0.80 to 1.32)
  Normal eGFR 161 83 0.3 308.9 (249.1 to 383.0) 1.00 (Reference) 1.00 (Reference)
(b) Hip fracture mortality post-hip fracture
  CKD stages 3–5† 915 183 1.4 134.1 (116.0 to 155.0) 1.39 (0.92 to 2.09) 0.79(0.51 to 1.22)
  CKD stage 5† 2 0 0.0 – – – 
  CKD stage 4 77 24 0.1 299.3 (200.6 to 446.5) 3.09 (1.78 to 5.39) 1.88 (1.02 to 3.47)
  CKD stage 3b 320 72 0.4 162.7 (129.1 to 204.9) 1.68 (1.07 to 2.63) 0.85 (0.53 to 1.37)
  CKD stage 3a 516 87 0.8 103.7 (84.0 to 127.9) 1.07 (0.69 to 1.66) 0.71 (0.45 to 1.12)
  Normal eGFR 161 26 0.3 96.8 (65.9 to 142.1) 1.00 (Reference) 1.00 (Reference)
The number of hip fracture deaths are not the same in tables 3b and 2b because:
1. Four individuals with CKD stages 3–5 died on date of hip fracture admission and are not included in the number of deaths in table 3.
2. A further 15 individuals had no record of a hip fracture admission but had a hip fracture-related death, and are therefore not included in the 
population for post-hip fracture mortality. Of these, 11 had CKD stages 3–5, with an average age of 87. Some died within a few days of index 
date. They had multiple and varied other causes of death, hip fracture was not the first or second cause for any. Four had normal eGFR, with 
an average age of 86. All died within 3 days of index date, and did not have hip fracture recorded as first, second or third cause of death.
*Adjusted for age, sex, Charlson Comorbidity Index score, deprivation, proteinuria and rurality (all variables remained in model).
†CKD stage 5 does not include dialysis or transplants.
CKD, chronic kidney disease; eGFR, estimated glomerular filtration rate; MRR, mortality rate ratio; PY, patient-years.
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addition, CKD may be a marker for frailty, leading to falls 
and an increased risk of fracture.
In keeping with some14 16 but not all17 reports, we have 
shown that hip fracture incidence is increased in individ-
uals with CKD. We showed this effect is best demonstrated 
when hip fracture incidence is measured with admis-
sions but also present when measured with deaths. We 
demonstrated that this increased risk was present across 
all ages; few previous studies included all age ranges16 34 
and many only included the elderly.15 35–37 We have shown 
that despite both CKD and hip fractures being more 
common in women, this effect of CKD on hip fracture 
incidence was also raised in men, something that has 
rarely been demonstrated.34 We demonstrated that worse 
CKD stage was associated with increased fracture admis-
sion risk (even after accounting for confounders), as 
reported by Naylor et al.14 However, we found the effect 
attenuated and not associated in CKD stage 5 due to less 
statistical power since, unlike Naylor et al14 we excluded 
RRT patients from stage 5 and reported RRT as a sepa-
rate group. Our finding that hip fracture incidence when 
measured with deaths was only increased among those 
with more advanced CKD (stages 3b and 4, but not 3a), 
supports a previous study in patients ≥75 years.18
We found that post-hip fracture mortality, among those 
who had a hip fracture admission, was little affected by 
CKD stages 3–5 overall, except stage 4. Studies in general38 
and RRT populations39 have reported elevated subse-
quent mortality in individuals who suffer a hip fracture 
compared with their age-matched non-fractured peers. 
However, to our knowledge, few studies have investigated 
the effect of CKD on mortality post-hip fracture.19 20 40–42 
Three reported increased mortality risk with worse renal 
function, either eGFR20 or creatinine,41 42 and one found 
no mortality risk with worse creatinine after adjusting 
for confounders.40 All of these studies, however, only 
included older patients and were based on single admis-
sion creatinine or eGFR, thus, deranged creatinine could 
be due to acute kidney injury (AKI). A further study 
relied on hospital admission coding for hip fractures with 
surgical repair, and a concurrent code for CKD or other-
wise,19 thus limiting CKD ascertainment. Our finding of 
an effect with stage 4 CKD is consistent with the literature 
generally—that mortality risk increases with renal func-
tion decline. However, in our study the lack of effect with 
stage 5 is likely due to less statistical power.
This study had several strengths. To our knowledge, 
this is the first study to report hip fracture incidence 
using both admission and death records, allowing direct 
comparison with studies that have used either of these 
methods. The lack of a consistent effect of CKD on frac-
ture incidence when measured by admission versus death 
demonstrates the importance of methods of measure-
ment in assessing such an outcome. Fractures are more 
likely to be recorded during an admission than at death, 
since for admission, a fracture is likely to be a major 
event, whereas for a death, many other factors may 
have contributed, and time between fracture and death 
recording may be lengthy. In our cohort, 1076 individuals 
had a hip fracture recorded from an admission compared 
with only 228 having a hip fracture recorded at death. 
GLOMMS-II, a large, population-based cohort including 
adults ≥15 years, uses valid methods for assessing comor-
bidity,43 identifying individuals with CKD,22 and has 
data linkage to long-term outcome data. Importantly, all 
biochemistry is provided by a single biochemistry service, 
whether inpatient, outpatient or community. This mini-
mises loss of baseline and follow-up data, avoids selec-
tion biases in recruitment, and enables assessment of the 
relationship between CKD and hip fracture over the full 
range of adult ages and CKD stages 3–5 groups. The use 
of at least two serum creatinine measurements to identify 
CKD (as per KDIGO),24 25 is a great strength compared 
with the majority of previous studies, which used only one 
measurement, therefore risking identifying episodes of 
AKI as CKD15; AKI itself being a risk factor for mortality 
and often complicates hospital admissions.23 Access to 
biochemistry results allowed us to demonstrate the effect 
of CKD more completely than studies where CKD diag-
nosis is based on healthcare coding alone.16 19
However, our study had limitations. We assessed hip frac-
ture from hospital episode data, and while most patients 
with a hip fracture are admitted to hospital, we recognise 
that a very small number may not be admitted. However, 
we postulate this would be low numbers (we noted only 
15 individuals who died with hip fracture as cause of 
death without a prior hip fracture admission). We only 
considered hip fractures, acknowledging that CKD may 
be associated with other fracture sites, but assuming that 
hip fractures would have more complete admission data, 
and have been used as a tracer condition for fragility frac-
tures at other sites.44 The GLOMMS-II cohort inception 
was 2003, with follow-up to 2009. However, national data 
suggest that age-standardised and sex-standardised rates 
of hip fracture admissions have been stable from 2003 
for over a decade.45 In addition, although new treatments 
have become available since 2003, treatment of hyper-
parathyroidism in patients with less advanced CKD, who 
make up the majority of this cohort, has changed little. 
We did not take into account the competing risk of death, 
which has been reported to result in an overestimation of 
the excess risk of hip fracture,16 however, we have demon-
strated the high fracture burden seen. Therefore, hip 
fracture avoidance is important and specifically measures 
to address modifiable risk factors in this population. We 
were unable to adjust for some factors that have been 
associated with fracture risk, including previous frac-
ture and low bone mineral density (see footnote under 
table 2), however, whatever an individual’s risk factors 
are, we have demonstrated the high risk for the popu-
lation as a whole. Although we did not include individ-
uals with CKD stage 1 or 2, 94% of those with normal 
eGFR did not have proteinuria measured. Therefore, we 
cannot rule out the possibility that some individuals in 
the normal eGFR comparison group could be CKD stage 
1 or 2. Finally, in this analysis, renal status was assessed at 
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baseline, thus, progression of CKD has not been taken 
into account. We would therefore recommend that the 
relationship between CKD progression and risk of frac-
ture be investigated in future research.
The findings of this study are directly applicable to 
Scottish healthcare, and likely applicable across the UK 
and many worldwide settings. Vitamin D exposure may 
be lower at extreme latitudes, and may contribute to frac-
ture rate. However, in our study, the exposed (CKD) and 
unexposed (normal eGFR) groups were from the same 
population, and Vitamin D exposure would be equiv-
alent, therefore, the relative risk is likely to be relevant 
internationally. The results summarise the workload 
faced by health services as a result of CKD-related bone 
disease. Our finding that individuals with CKD, partic-
ularly more advanced, are at higher risk of hip fracture 
should encourage better assessment and management of 
risk factors for fracture and falls, including in younger 
patients with CKD. Risk factors for fracture include modi-
fiable risk factors (alcohol use, smoking, body mass, bone 
mineral density and medication) and non-modifiable risk 
factors (age, gender, previous fracture and early meno-
pause). Frailty has been associated with falls46 and frac-
tures46 47 in both the general and dialysis populations; 
and falls are common in those on dialysis.48 Falls risk 
assessment should therefore be integral to fracture risk 
assessment,32 and perhaps CKD reviews should there-
fore include consideration of interventions that might 
improve impaired balance and fracture risks. A reduction 
in hip fracture incidence would potentially reduce the 
number of fracture-related deaths overall.
COnClusIOn
By using different measures of hip fracture incidence and 
mortality, we have demonstrated why other studies have 
shown mixed associations between CKD and hip fracture. 
Hip fracture incidence was higher in individuals with 
CKD compared with those with normal eGFR particularly 
where measured with admissions. However, following 
a hip fracture, CKD did not increase post-hip fracture 
mortality except in those with CKD stage 4. Nonetheless, 
a reduction in hip fracture incidence in those with CKD 
would reduce the number of deaths after hip fracture in 
the population.
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